New agents for treating dry eye syndrome

Simon E. Skalicky; Con Petsoglou; Avinash Gurbaxani; Clare L. Fraser; Peter McCluskey

doi:10.1007/s11882-012-0321-0

New agents for treating dry eye syndrome

Simon E. Skalicky^*, Con Petsoglou, Avinash Gurbaxani, Clare L. Fraser, Peter McCluskey

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.

Original language	English
Pages (from-to)	322-328
Number of pages	7
Journal	Current Allergy and Asthma Reports
Volume	13
Issue number	3
DOIs	https://doi.org/10.1007/s11882-012-0321-0
Publication status	Published - Jun 2013
Externally published	Yes

Keywords

Anti-inflammatory agents
Artificial tears
Corticosteroids
Cyclosporine A
Dry eye syndrome
Essential fatty acids
New agents
NSAIDs
Ocular lubricants
Secretagogues
Topical therapies
Treatment

Access to Document

10.1007/s11882-012-0321-0

Cite this

@article{267b853e89d74b2082b266bbe15b12d6,

title = "New agents for treating dry eye syndrome",

abstract = "Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.",

keywords = "Anti-inflammatory agents, Artificial tears, Corticosteroids, Cyclosporine A, Dry eye syndrome, Essential fatty acids, New agents, NSAIDs, Ocular lubricants, Secretagogues, Topical therapies, Treatment",

author = "Skalicky, {Simon E.} and Con Petsoglou and Avinash Gurbaxani and Fraser, {Clare L.} and Peter McCluskey",

year = "2013",

month = jun,

doi = "10.1007/s11882-012-0321-0",

language = "English",

volume = "13",

pages = "322--328",

journal = "Current Allergy and Asthma Reports",

issn = "1529-7322",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - New agents for treating dry eye syndrome

AU - Skalicky, Simon E.

AU - Petsoglou, Con

AU - Gurbaxani, Avinash

AU - Fraser, Clare L.

AU - McCluskey, Peter

PY - 2013/6

Y1 - 2013/6

N2 - Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.

AB - Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.

KW - Anti-inflammatory agents

KW - Artificial tears

KW - Corticosteroids

KW - Cyclosporine A

KW - Dry eye syndrome

KW - Essential fatty acids

KW - New agents

KW - NSAIDs

KW - Ocular lubricants

KW - Secretagogues

KW - Topical therapies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84877924994&partnerID=8YFLogxK

U2 - 10.1007/s11882-012-0321-0

DO - 10.1007/s11882-012-0321-0

M3 - Review article

C2 - 23129303

AN - SCOPUS:84877924994

VL - 13

SP - 322

EP - 328

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 3

ER -

New agents for treating dry eye syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this